Literature DB >> 22257176

Low testosterone level predicts prostate cancer in re-biopsy in patients with high grade prostatic intraepithelial neoplasia.

Eduard García-Cruz1, Marta Piqueras, Maria José Ribal, Jorge Huguet, Rodrigo Serapiao, Lluis Peri, Laura Izquierdo, Antonio Alcaraz.   

Abstract

UNLABELLED: What's known on the subject? and What does the study add? High grade prostatic intraepithelial neoplasia (HGPIN) is a risk factor for prostate cancer (PCa), but only multifocality is an indication for early rebiopsy. Other risk factors for PCa development from HGPIN remain unknown. PCa is related to testosterone. Testosterone has been proven to be linked to PCa detection and poor prognosis PCa. This study shows that low free and bioavailable testosterone levels are associated with an increased risk of PCa in a rebiopsy after HGPIN diagnosis. Men with low testosterone levels and HGPIN could therefore be considered a high-risk cohort for developing PCa.
OBJECTIVE: To determine the relevance of the hormonal profile of patients with high grade prostatic intraepithelial neoplasia (HGPIN) and its relationship to prostate cancer (PCa) in rebiopsy. PATIENTS AND METHODS: We prospectively analysed 82 consecutive patients with a diagnosis of HGPIN without PCa in a prostate biopsy between September 2007 and December 2009. Of these 82 patients, 45 underwent rebiopsy and their hormonal profile was determined (testosterone and sex hormone-binding globulin [SHBG]) as part of our clinical protocol. Patient age, PSA level, prostate volume, PSA density, testosterone, free testosterone, bioavailable testosterone and SHBG were recorded prospectively. A comparative study between those patients with a positive rebiopsy and those with a negative rebiopsy was performed.
RESULTS: We found that free testosterone (P = 0.04), bioavailable testosterone (P = 0.04) and SHBG (P = 0.02) were significantly associated with a positive rebiopsy. Other variables such as age (P = 0.745), PSA level (P = 0.630), prostate volume (P = 0.690), PSA density (P = 0.950), testosterone (P = 0.981) and prostatic intraepithelial neoplasia multifocality (P = 0.777) were not associated with the presence of adenocarcinoma in the rebiopsy.
CONCLUSIONS: Patients with adenocarcinoma of the prostate after a diagnosis of HGPIN have higher SHBG levels and lower calculated free testosterone levels than patients with a negative rebiopsy. Testosterone levels might be a useful indication for rebiopsy after HGPIN diagnosis.
© 2012 BJU INTERNATIONAL.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22257176     DOI: 10.1111/j.1464-410X.2011.10876.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  13 in total

Review 1.  The safety of testosterone supplementation therapy in prostate cancer.

Authors:  James M Dupree; Gavin M Langille; Mohit Khera; Larry I Lipshultz
Journal:  Nat Rev Urol       Date:  2014-07-29       Impact factor: 14.432

Review 2.  Testosterone and prostate cancer: an evidence-based review of pathogenesis and oncologic risk.

Authors:  Jason E Michaud; Kevin L Billups; Alan W Partin
Journal:  Ther Adv Urol       Date:  2015-12

Review 3.  Hypogonadism and its treatment among prostate cancer survivors.

Authors:  Edward J Choi; Perry Xu; Farouk M El-Khatib; Linda M Huynh; Faysal A Yafi
Journal:  Int J Impot Res       Date:  2020-12-12       Impact factor: 2.896

4.  Effects of Testosterone on Benign and Malignant Conditions of the Prostate.

Authors:  Amin S Herati; Taylor P Kohn; Peter R Butler; Larry I Lipshultz
Journal:  Curr Sex Health Rep       Date:  2017-04-26

Review 5.  To treat or not to treat with testosterone replacement therapy: a contemporary review of management of late-onset hypogonadism and critical issues related to prostate cancer.

Authors:  Bruce R Kava
Journal:  Curr Urol Rep       Date:  2014-07       Impact factor: 3.092

6.  Pituitary sex hormones enhance the pro‑metastatic potential of human lung cancer cells by downregulating the intracellular expression of heme oxygenase‑1.

Authors:  Ahmed Abdelbaset-Ismail; Daniel Pedziwiatr; Gabriela Schneider; Jacek Niklinski; Radoslaw Charkiewicz; Marcin Moniuszko; Magda Kucia; Mariusz Z Ratajczak
Journal:  Int J Oncol       Date:  2016-12-02       Impact factor: 5.650

7.  The role of the serum testosterone levels as a predictor of prostate cancer in patients with atypical small acinar proliferation at the first prostate biopsy.

Authors:  Lucio Dell'Atti; Andrea B Galosi
Journal:  Asian J Androl       Date:  2018 Jan-Feb       Impact factor: 3.285

8.  The association between the levels of serum ferritin and sex hormones in a large scale of Chinese male population.

Authors:  Zhenfang Liu; Fanghui Ye; Haiying Zhang; Yong Gao; Aihua Tan; Shijun Zhang; Qiang Xiao; Bing Zhang; Lulu Huang; Bingbing Ye; Xue Qin; Chunlei Wu; Zheng Lu; Youjie Zhang; Ming Liao; Xiaobo Yang; Zengnan Mo
Journal:  PLoS One       Date:  2013-10-11       Impact factor: 3.240

Review 9.  Testosterone deficiency, cardiac health, and older men.

Authors:  G Hackett; M Kirby; A J Sinclair
Journal:  Int J Endocrinol       Date:  2014-04-10       Impact factor: 3.257

10.  First results of the double-blind randomized placebo-controlled multicenter clinical trial of DIM-based therapy designed as personalized approach to reverse prostatic intraepithelial neoplasia (PIN).

Authors:  Mikhail Paltsev; Vsevolod Kiselev; Vadim Drukh; Ekaterina Muyzhnek; Igor Kuznetsov; Evgeniya Andrianova; Pavel Baranovskiy
Journal:  EPMA J       Date:  2016-04-02       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.